| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TIPS.2011.07.004 |
| P953 | full work available online at | https://api.elsevier.com/content/article/PII:S0165614711001350?httpAccept=text/plain |
| https://api.elsevier.com/content/article/PII:S0165614711001350?httpAccept=text/xml | ||
| P698 | PubMed publication ID | 22088767 |
| P2093 | author name string | Kerry-Anne Rye | |
| Philip Barter | |||
| P2860 | cites work | A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly | Q23913851 |
| Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels | Q24562095 | ||
| Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial | Q24648125 | ||
| Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study | Q24649155 | ||
| Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial | Q28236480 | ||
| Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib | Q28240147 | ||
| Effect of torcetrapib on the progression of coronary atherosclerosis | Q28295023 | ||
| Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia | Q28295044 | ||
| Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials | Q29617910 | ||
| Effects of torcetrapib in patients at high risk for coronary events | Q29619609 | ||
| Intensive versus moderate lipid lowering with statins after acute coronary syndromes | Q29619716 | ||
| Transfers and exchanges of esterified cholesterol between plasma lipoproteins | Q34662113 | ||
| HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events | Q34693837 | ||
| Major lipids, apolipoproteins, and risk of vascular disease | Q35771393 | ||
| Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone | Q36736504 | ||
| Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk | Q37193386 | ||
| Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation | Q38497153 | ||
| Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels | Q39700827 | ||
| Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition | Q39891782 | ||
| Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits | Q40166036 | ||
| A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits | Q40866383 | ||
| Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib | Q42562376 | ||
| Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease | Q42807626 | ||
| Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition | Q43201715 | ||
| Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. | Q43230598 | ||
| Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial | Q43246793 | ||
| Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosc | Q46231225 | ||
| Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. | Q53569234 | ||
| Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression | Q54419966 | ||
| Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein | Q59070155 | ||
| A Low Prevalence of Coronary Heart Disease among Subjects with Increased High-Density Lipoprotein Cholesterol Levels, Including Those with Plasma Cholesteryl Ester Transfer Protein Deficiency | Q61962950 | ||
| Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species | Q70283890 | ||
| Effect of Antisense Oligonucleotides against Cholesteryl Ester Transfer Protein on the Development of Atherosclerosis in Cholesterol-fed Rabbits | Q74230827 | ||
| Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis | Q74290884 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | circulatory system | Q11068 |
| P304 | page(s) | 694-699 | |
| P577 | publication date | 2011-11-14 | |
| P1433 | published in | Trends in Pharmacological Sciences | Q2451474 |
| P1476 | title | Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now? | |
| Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now? | |||
| P478 | volume | 32 |
| Q34658086 | A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations |
| Q57118481 | Alterations in gut microbial function following liver transplant |
| Q61800652 | Apolipoprotein A-I enhances insulin-dependent and insulin-independent glucose uptake by skeletal muscle |
| Q44749348 | Assessing the mechanisms of cholesteryl ester transfer protein inhibitors. |
| Q38546242 | Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs |
| Q37118772 | Hyodeoxycholic acid improves HDL function and inhibits atherosclerotic lesion formation in LDLR‐knockout mice |
| Q36037988 | Molecular mechanisms of vascular effects of High‐density lipoprotein: alterations in cardiovascular disease |
| Q37254899 | Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes |
| Q35477219 | New Diterpenes from Cultures of the Fungus Engleromyces goetzii and Their CETP Inhibitory Activity |
| Q97521140 | Plasma lipidomic biomarker analysis reveals distinct lipid changes in vascular dementia |
| Q35034769 | Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer's disease |
| Q28569962 | Postprandial changes in high density lipoproteins in rats subjected to gavage administration of virgin olive oil |
| Q30155210 | Structural features of cholesteryl ester transfer protein: a molecular dynamics simulation study |
| Q35958413 | The inhibition of cholesteryl ester transfer protein: a long and winding road |
| Q38122628 | Validating therapeutic targets through human genetics |
Search more.